Product Code: GDHCER125-16
Major depressive disorder (MDD), also known as clinical depression or major depression, is widely recognized as a mood disorder that may lead to a variety of emotional and physical problems. MDD is characterized by persistent feelings of sadness, anger, irritability or frustration, loss of interest in activities, and overeating or loss of appetite that can last from days to months, and alternates with episodes of wellness. Little is known about the etiology of MDD; however, research suggests that there may be combinations of genetic, biological, environmental, and psychological factors that potentially increase the risk of MDD.
GlobalData epidemiologists forecast that the 12-month total prevalent cases of MDD in the 7MM will increase from 37,157,683 12-month total prevalent cases in 2015 to 38,142,749 12-month total prevalent cases in 2025, at an Annual Growth Rate (AGR) of 0.27%. The US will have the highest number of 12-month total prevalent cases of MDD among the 7MM throughout the forecast period, while Japan will have the least number of 12-month total prevalent cases of MDD. As GlobalData epidemiologists used steady prevalence proportions of MDD over the forecast period, the growth in 12-month total prevalent cases in each market can be attributed to the change in population demographics.
GlobalData epidemiologists utilized country-specific and nationally representative peer-reviewed publications to forecast the 12-month total prevalent cases of MDD. The use of consistent methodology across the 7MM allows for a meaningful comparison of the forecast of 12-month total prevalent cases of MDD in these markets. Additionally, the 12-month total prevalent cases of MDD in each of the 7MM are segmented by severity, which can be of importance for predicting the prognosis and course of treatment. Lastly, the 12-month total prevalent cases of MDD in each of the 7MM are further segmented by age and sex in order to provide a more detailed analysis of the patient population.
- The Major Depressive Disorder (MDD) EpiCast Report provides an overview of the risk factors and global trends of MDD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of 12-month total prevalent cases of MDD segmented by age (18-19 years, in five-year increments from ages 20-84 years, and ending at ages 85 years and older), sex, and severity in these seven markets.
- The MDD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The MDD EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global MDD market.
- Quantify patient populations in the global MDD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MDD therapeutics in each of the markets covered.
- Identify the percentage of MDD 12-month total prevalent cases by age, sex, and severity.
Table of Contents
1. Table of Contents
- 1.1. List of Tables
- 1.2. List of Figures
- 2.1. Disease Background
- 2.2. Risk Factors and Comorbidities
- 2.3. Global Trends
- 2.4. Forecast Methodology
- 2.4.1. Sources Used Tables
- 2.4.2. Forecast Assumptions and Methods
- 2.4.3. Sources Not Used
- 2.5. Epidemiological Forecast for MDD (2015-2025)
- 2.5.1. 12-Month Total Prevalent Cases of MDD
- 2.5.2. Age-Specific 12-Month Total Prevalent Cases of MDD
- 2.5.3. Sex-Specific 12-Month Total Prevalent Cases of MDD
- 2.5.4. Age-Standardized 12-Month Total Prevalence of MDD
- 2.5.5. 12-Month Total Prevalent Cases of MDD by Severity
- 2.6. Discussion
- 2.6.1. Epidemiological Forecast Insight
- 2.6.2. Limitations of the Analysis
- 2.6.3. Strengths of the Analysis
- 3.1. Bibliography
- 3.2. Physicians and Specialists Included in this Study
- 3.3. About the Authors
- 3.3.1. Epidemiologists
- 3.3.2. Reviewers
- 3.3.3. Global Director of Therapy Analysis and Epidemiology
- 3.4. About GlobalData
- 3.5. About EpiCast
- 3.6. Disclaimer
List of Tables
- Table 1: DSM-IV Diagnostic Criteria for MDD
- Table 2: Risk Factors and Comorbidities for MDD
- Table 3: Prevalence of the Most Frequent Psychiatric Comorbidities in Individuals With and Without MDD, Ages 18-64 Years
- Table 4: 7MM, Total Prevalence (%) of MDD According to the DSM-IV Criteria, ≥18 Years
- Table 5: 7MM, Total Prevalence (%) of MDD According to the DSM-III Criteria
- Table 6: 7MM, Sources Used to Forecast the 12-Month Total Prevalence of MDD
- Table 7: Sources Used to Forecast the 12-Month Total Prevalent Cases of MDD by Severity
- Table 8: 7MM, Sources Not Used in Epidemiological Forecast for the 12-Month Total Prevalent Cases of MDD
- Table 9: 7MM, 12-Month Total Prevalent Cases of MDD, Ages ≥18Years, Both Sexes, N, Selected Years 2015-2025
- Table 10: 7MM, 12-Month Total Prevalent Cases of MDD, by Age, Both Sexes, N (Row %), 2015
- Table 11: 7MM, 12-Month Total Prevalent Cases of MDD, by Sex, Ages ≥18 Years, N (Row %), 2015
- Table 12: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2016
List of Figures
- Figure 1: 7MM, 12-Month Total Prevalent Cases of MDD, Ages ≥18 Years, Both Sexes, N, 2015-2025
- Figure 2: 7MM, 12-Month Total Prevalent Cases of MDD, by Age, Both Sexes, N, 2015
- Figure 3: 7MM, 12-Month Total Prevalent Cases of MDD, by Sex, Ages ≥18 Years, N, 2015
- Figure 4: 7MM, Age-Standardized 12-Month Total Prevalence (%) of MDD, by Sex, Ages ≥18 Years, 2015
- Figure 5: 7MM, 12-Month Total Prevalent Cases of MDD by Severity, Both Sexes, Ages ≥18 Years, 2015